Details

Autor(en) / Beteiligte

• Payne, Rebecca P.
• Austin, James A.
• Skelly, Donal T.
• Meardon, Naomi
• Faustini, Sian
• Al-Taei, Saly
• Moore, Shona C.
• Hering, Luisa M.
• Angyal, Adrienn
• Brown, Rebecca
• Nicols, Alexander R.
• Gillson, Natalie
• Dobson, Susan L.
• Amini, Ali
• Supasa, Piyada
• Cross, Andrew
• Bridges-Webb, Alice
• Linder, Aline
• Altmann, Thomas
• Whitham, Rachel
• Phillips, Eloise
• Hargreaves, Alexander
• Shields, Adrian
• Foulkes, Sarah
• Johnson, Sile
• Wootton, Daniel G.
• Conlon, Christopher P.
• Matthews, Philippa C.
• Frater, John
• Deeks, Alexandra S.
• Pollard, Andrew J.
• Brown, Anthony
• Rowland-Jones, Sarah L.
• Mongkolsapaya, Juthathip
• Hopkins, Susan
• Dold, Christina
• Richter, Alex
• Carroll, Miles
• Screaton, Gavin
• de Silva, Thushan I.
• Turtle, Lance
• Klenerman, Paul
• Dunachie, Susanna
• Abuelgasim, Hibatullah
• Adland, Emily
• Adlou, Syed
• Akther, Hossain Delowar
• Ansari, M. Azim
• Arancibia-Cárcamo, Carolina V.
• Bayley, Martin
• Brown, Helen
• Chand, Meera
• Chawla, Anu
• Chinnakannan, Senthil
• Cutteridge, Joseph
• de Lara, Catherine
• Denly, Lucy
• Diffey, Ben
• Dimitriadis, Stavros
• Drake, Thomas M.
• Donnison, Timothy
• Dupont, Maeva
• Gardiner, Siobhan
• Gilbert-Jarmillo, Javier
• Goulder, Philip
• Hackstein, Carl-Philipp
• Hambleton, Sophie
• Haniffa, Muzlifah
• Haworth, Jenny
• Holmes, Jennifer
• Jämsén, Anni
• Jones, Chris
• Kelly, Sinead
• Kirk, Rosemary
• Knight, Michael L.
• Lawrie, Allan
• Lee, Lian
• Lett, Lauren
• Lim, Nicholas
• Mentzer, Alexander J.
• O’Donnell, Denise
• Payne, Brendan A.I.
• Provine, Nicholas
• Robinson, Nichola
• Romaniuk, Leigh
• Simmons, Beatrice
• Spegarova, Jarmila S.
• Stephenson, Emily
• Subramaniam, Kris
• Travis, Simon
• Tucker, Stephanie
• Watson, Adam
• Watson, Lisa
• Weeks, Esme
• Wilson, Robert
• Wood, Steven
• Wright, Rachel
• Xiao, Huiyuan
• Zawia, Amira A.T.

Titel

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Ist Teil von

• Cell, 2021-11, Vol.184 (23), p.5699-5714.e11

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4+ T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol. [Display omitted] •BNT162b2 vaccine with an extended interval between doses is highly protective•Antibody levels were higher after the extended regimen compared with the short regimen•The extended regimen enriches for virus-specific CD4+ T cells expressing IL-2•Antibody levels wane after each dose, but B and T cell pools are maintained After giving a primary dose, delaying administration of a second dose of BNT162b2 COVID-19 vaccine up to 6–14 weeks continues to provide strong protection and contributes to favorable antibody, B cell, and T cell responses.